Carbohydrate mimics (“glycomimetic” compounds) are an important new class of drugs, and GlycoMimetics, Inc. is positioned to lead this promising field.

GlycoMimetics has a specialized platform technology which is producing first-in-class proprietary drug candidates with an initial focus on inflammation, blood cancers, and infectious disease. We are achieving key milestones in advancing our programs.  Our lead compound, an acute anti-inflammatory agent, is in clinical trials, and based on our in-depth understanding of the science of carbohydrate medicines, GlycoMimetics has also discovered an exciting pipeline of follow-on opportunities. In addition, GlycoMimetics has established a robust intellectual property portfolio, an experienced management team and a strong syndicate of investors.